Ranpirnase - An antitumour ribonuclease: Its potential role in malignant mesothelioma

Expert Opinion on Biological Therapy

Volumn 6, Issue 4, 2006, Pages 391-399

  Pavlakis, Nick ^a   Vogelzang, Nicholas J ^b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b NEVADA CANCER INSTITUTE   (United States)

Author keywords

Antineoplastic chemotherapy; Antitumour ribonucleases; Malignant mesothelioma; Ranpirnase

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLIC ACID ANTAGONIST; GEMCITABINE; NAVELBINE; OXALIPLATIN; RALTITREXED; RANPIRNASE;

ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ASTHENIA; CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DYSPNEA; EDEMA; FEVER; HUMAN; MALIGNANT MESOTHELIOMA; META ANALYSIS; MUCOSAL DISEASE; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PARESTHESIA; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; MESOTHELIOMA; RIBONUCLEASES;

EID: 33645761337     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.4.391     Document Type: Review

References (48)

1. CARBONE M, PASS HI, MIELE L, BOCHATTA M: New developments about the association of SV40 with human mesothelioma. Oncogene (2003) 22(33):5173-5180.
2. CARBONE M, RDZANEK MA: Pathogenesis of malignant mesothelioma. Clin. Lung Cancer (2004) 5(Suppl. 2):S46-S50.
3. KAZAN-ALLEN L: Asbestos and mesothelioma: worldwide trends. Lung Cancer (2005) 49(Suppl. 1):S3-S8.
4. ZELLOS L, CHRISTIANI DC: Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac. Surg. Clin. (2004) 14(4):469-477.
5. ZELLOS LS, SUGARBAKER DJ: Multimodality treatment of diffuse malignant pleural mesothelioma. Semin. Oncol. (2002) 29(1):41-50.
6. MAZIAK DE, GAGLIARDI A, HAYNES AE, MACKAY JA, EVANS WK: Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer (2005) 48(2):157-169.
7. MARTINO D, PASS HI: Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin. Lung Cancer (2004) 5(5):290-298.
8. BERGHMANS T, PAESMANS M, LALAMI Y et al.: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer (2002) 38(2):111-121.
9. TOMEK S, MANEGOLD C: Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer (2004) 45(Suppl. 1):S103-S119.
10. VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21(14):2636-2644. Pivotal Phase III study of pemetrexed and cisplatin in mesothelioma confirming a survival advantage compared with cisplatin alone.
11. PAOLETTI P, PISTOLESI M, RUSTHOVEN JJ et al.: Correlation of pulmonary function tests with best tumor response status: Results from the Phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. (2003) 22:659 (abstract 2651).
12. GRALLA RJ, HOLLEN PJ, LIEPA AM et al.: Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed + cisplatin versus cisplatin trial using the LCSS-meso instrument. Proc. Am. Soc. Clin. Oncol. (2003) 22:621 (abstract 2496).
13. VAN MEERBEECK JP, GAAFAR R, MANEGOLD C et al.: Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. (2005) 23(28):6881-6889. Second Phase III study in mesothelioma confirming survival advantage of an antifolate (in this case raltixtrexed) combined with cisplatin compared with cisplatin alone.
14. FIZAZI K, CALIANDRO R, SOULIE P A et al.: Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur. J. Cancer (2000) 36(12):1514-1521.
15. FIZAZI K, DUCREUX M, RUFFIE P et al.: Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol. (2000) 18(11):2293-2300.
16. FIZAZI K, DOUBRE H, LE CHAVELIERT et al.: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. J. Clin. Oncol. (2003) 21(2):349-354.
17. VOGELZANG NJ: Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?[comment]. J. Clin. Oncol. (1999) 17(8):2626-2627.
18. MIKULSKI SM, COSTANZI JJ, VOGELZANG NJ et al.: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. (2002) 20(1):274-281. Pivotal Phase II study of ranpirnase in 105 patients with mesothelioma, 39 of whom had received prior chemotherapy, suggesting a possible survival benefit allowing for baseline prognostic factors.
19. MANEGOLD C, SYMANOWSKI J, GATZEMEIER U et al.: Second-line (post-study) chemotherapy received by patients treated in the Phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. (2005) 16(6):923-927.
20. GIACCONE G, O'BRIEN ME, BYRNE MJ, BARD M, KAUKEL E, SMIT B: Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur. J. Cancer (2002) 38(Suppl. 8):S19-S24.
21. ARDELT W, MIKULSKI SM, SHOGEN K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J. Biol. Chem. (1991) 266(1):245-251.
22. IRIE M, NITTA K, NONAKA T: Biochemistry of frog ribonucleases. Cell. Mol. Life Sci. (1998) 54(8):775-784.
23. MOSIMANN SC, JOHNS KL, ARDELT W, MIKULSKI SM, SHOGEN K, JAMES MN: Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos. Proteins (1992) 14(3):392-400.
24. LELAND PA, SCHULTZ LW, KIM BM, RAINES RT: Ribonuclease A variants with potent cytotoxic activity. Proc. Natl. Acad. Sci. USA (1998) 95(18):10407-10412.
25. WU Y, MIKULSKI SM, ARDELT W, RYBAK SM, YOULE RJ: A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J. Biol. Chem. (1993) 268(14):10686-10693.
26. IORDANOV MS, RYABININA OP, WONG J et al.: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res. (2000) 60(7):1983-1994.
27. DARZYNKIEWICZ Z, CARTER SP, MIKULSKI SM, ARDELT WJ, SHOGEN K: Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinetics (1988) 21(3):169-182.
28. KIM BM, KIM H, RAINES RT LEE Y: Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem. Biophys. Res. Commun. (2004) 315(4):976-983.
29. SAXENA SK, SHOGEN K, WOJCIECH A: ONCONASE and its therapeutic potential. Lab. Med. (2005) 34(5):380-387.
30. MIKULSKI SM, VIERA A, ARDELT W, MENDUKE H, SHOGEN K: Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity. Cell Tissue Kinetics (1990) 23(3):237-246.
31. MIKULSKI SM, VIERA A, SHOGEN K: In vitro synergism between a novel amphibian oocytic ribonuclease (ONCONASE) and tamoxifen, lovastatin and cisplatin, in human OVCAR-3 ovarian carcinoma cell line. Int. J. Oncol. (1992) 1:77-85.
32. MIKULSKI SM, NEWTON DL, WILTROUT RH et al.: Onconase and doxorubicin synergy in prolonging survival of MDA-MB-231 human breast cancer-bearing nude mice. Proc. Am. Assoc. Cancer Res. (1999) 40:491 (abstract 3246).
33. RYBAK SM, PEARSON JW, FOGLER WE et al.: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J. Natl Cancer Inst. (1996) 88(11):747-753.
34. RAMOS-NINO ME, VIANALE G, SABO-ATTWOOD T et al.: Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol. Cancer Ther. (2005) 4(5):835-842.
35. COSTANZI J, DARZYNKIEWICZ Z, CHUN H: The use of Onconase (ONC) for patients (pts) with advanced malignant mesothelioma (MM). Proc. Am. Soc. Clin. Oncol. (1996) 15:452 (abstract A1414).
36. MIKULSKI SM, ARDELT W, SHOGEN K, BERNSTEIN EH, MENDUKE H: Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J. Natl Cancer Inst. (1990) 82(2):151-153.
37. VASANDANI VM, WU YN, MIKULSKI SM, YOULE RJ, SUNG C: Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily. Cancer Res. (1996) 56(18):4180-4186.
38. VASANDANI VM, BURRIS JA, SUNG C: Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother. Pharmacol. (1999) 44(2):164-169.
39. COSTANZI J, SIDRANSKY D, NAVON A, GOLDSWEIG H: Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. (2005) 23(7):643-650.
40. 2/week.
41. MIKULSKI SM, CHUN HG, MITTELMAN A et al.: Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: comparison of - ONCONASE® with other anticancer agents. Int. J. Oncol. (1995) 6(4):889-897.
42. PUCCIO C, MITTELMAN A, CHUN H et al.: A new anticancer Rnase (onconase): clinical trial in patients (pts) with breast cancer (BC). Proc. Am. Soc. Clin. Oncol. (1996):242a.
43. VOGELZANG NJ, AKLILU M, STADLER WM, DUMAS MC, MIKULSKI SM: A Phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest. New Drugs (1999) 3:255-260.
44. CHUN H, COSTANZI J, MITTELMAN A et al.: Phase I/II trial of onconase (ONC) plus tamoxifen (TMX) in patients (pts) with advanced pancreatic carcinoma (APC). Proc. Am. Soc. Clin. Oncol. (1995):517a.
45. HERNDON JE, GREEN MR, CHAHINIAN AP, CORSON JM, SUZUKI Y, VOGELZANG NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 113(3):723-731.
46. KORN EL, ARBUCK SG, PLUDA JM, SIMON R, KAPLAN RS, CHRISTIAN MC: Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. (2001) 19(1):265-272. A review of ideal clinical trial designs for cytostatic agents.
47. VOGELZANG N, TAUB R, SHIN D et al.: Phase III randomized trial of onconase (ONC) versus doxorubicin (DOX) in patients (Pts) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc. Am. Soc. Clin. Oncol. (2000):2274a.
48. EDWARDS JG, ABRAMS KR, LEVERMENT JN, SPYT TJ, WALLER DA, O'BYRNE KJ: Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax (2000) 55(9):731-735.